woman working in lab

Moving Prenatal Screening and Liquid Biopsy Forward

Shifting the Paradigm of Prenatal Screening

The name of our non-invasive prenatal test (NIPT) is appropriately called “UNITY” as it brings together fetal screening for aneuploidies and recessive conditions. It also represents uniting pregnant patients in more equitable care.

iStock-1135307739-scaled-e1656374638168
Unity logo

UNITY Screen™ is the only commercially available non-invasive prenatal screen that assesses fetal risk for aneuploidies, recessive conditions, and fetal antigens from a maternal blood draw at 10+ weeks into pregnancy. We are able to quantify the tiny DNA changes floating in cell-free DNA using our molecular counting technology.

UNITY does not require a paternal blood sample to assess fetal risk, supporting more equitable care and enabling more pregnancies at risk to be affected with recessive conditions to be identified early in pregnancy as compared to traditional carrier screening.

Learn More About Unity

Uncovering What’s Possible for Liquid Biopsy

Northstar Select™ and Northstar Response™ are liquid biopsy tests are now available for commercial use. Learn more on the Northstar product website.

Therapy Selection

The Northstar Select™ provides a prioritized list of mutations that are present in the tumor. The types of mutations detected include deletions, insertions, and point-mutations. At the same time, it helps rule-in / rule-out relationship of mutations to drugs and provides an accurate read on the covered genes.

Details

  • Broad genomic coverage
  • Low limit of detection
Learn More About Northstar Select
closeup of a hand holding a test tube with separated blood and plasma

Therapy Response

The Northstar Response™ provides longitudinal determination of cancer burden via methylation assessment.

Details

  • Multi cancer methylation signature (nucleotides are methylated in specific locations in cancers)
  • Quantification of changes in tumor burden enabled by our molecular counting technology
Learn More About Northstar Response
asian female scientist putting blood in Hamilton machine

Interested in a research collaboration? Get in touch or Discover Our Technology

Get In Touch

News & Media

View All

Media Coverage

GenomeWeb- BillionToOne Pushing Forward in Cancer Diagnostics With First Data on Response Monitoring Test

Read Article

Media Coverage

BioWorld MedTech Interview- BillionToOne test reduces need for Rhogam in 40% of Rh-negative pregnancies

Read Article

Press Releases

BILLIONTOONE MITIGATING RHOGAM(R) SHORTAGE WITH UNITY FETAL RhD™ NON-INVASIVE PRENATAL TEST

Read Article

Media Coverage

BillionToOne is recognized by Forbes as one of America’s Best Startup Employers for 2024!

Read Article

Press Releases

BILLIONTOONE ANNOUNCES ROSS TAYLOR AS CHIEF FINANCIAL OFFICER

Read Article

Press Releases

BillionToOne to Present at the 42nd Annual J.P. Morgan Healthcare Conference

Read Article

Press Releases

BillionToOne Announces Global Collaboration to Provide its UNITY Fetal Antigen™ Clinical Trial Assay in Johnson & Johnson Phase 3 Clinical Trial of Nipocalimab in Hemolytic Disease of the Fetus and Newborn

Read Article

Media Coverage

UNITY Fetal Risk Screen has earned a spot in AJHG’s Genomic Medicine Year in Review: 2023, recognized as a top 10 key advancement in applying genomics to clinical care.

Read Article

Media Coverage

BillionToOne recognized as one of the most promising digital health companies of 2023 by CB Insights

Read Article

Press Releases

BillionToOne Announces Clinical Outcomes Data for UNITY Fetal Risk™ Screen, Demonstrating Exceptional Accuracy in General Pregnancy Population

Read Article